Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

Rhea-AI Summary

Pulmonx (Nasdaq: LUNG) will report its fourth quarter and full year 2025 financial results after market close on Wednesday, March 4, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET and a live archived webcast will be available on the company investor website.

News Market Reaction – LUNG

+5.99%

6 alerts

+5.99% Session close to close

+2.0% Peak in 2 hr 13 min

$62.28M Market Cap

0.7x Rel. Volume

In the Feb 20 session, LUNG gained 5.99%, reflecting a notable positive market reaction. Argus tracked a peak move of +2.0% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +6.0% in the session following this news. A strong positive reaction aligns with how...

Analysis

The stock moved +6.0% in the session following this news. A strong positive reaction aligns with how Pulmonx has historically responded to clear corporate updates, such as conference participation or inducement grants. With shares already trading well below the 200-day MA and near the 52-week low, a sharp move could reflect positioning ahead of the upcoming earnings release. Investors would need to watch how any follow-on use of the $200,000,000 shelf and future financial results affect longer-term sentiment.

Key Figures

Earnings release date: March 4, 2026 Quarter covered: Fourth quarter 2025 Full-year period: Full year 2025 +2 more

5 metrics

Earnings release date March 4, 2026 Q4 and full-year 2025 financial results release after market close

Quarter covered Fourth quarter 2025 Period for upcoming financial results

Full-year period Full year 2025 Annual results to be reported

Conference call time PT 1:30 p.m. PT Scheduled start time for earnings call

Conference call time ET 4:30 p.m. ET Scheduled start time for earnings call

Historical Context

5 past events · Latest: Dec 03 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 03	Inducement equity grants	Neutral	+8.0%	Large RSU and PSU grants under 2025 Inducement Plan for new executives.
Nov 12	Q3 2025 earnings	Neutral	-6.2%	Q3 2025 results with revenue growth, high gross margin, and ongoing net loss.
Oct 27	Management transition	Neutral	-4.9%	CEO change, new COO/CFO, executive departures, and preliminary Q3 revenue update.
Oct 15	Earnings date notice	Neutral	-2.5%	Announcement of Q3 2025 earnings release date and conference call details.
Aug 26	Investor conferences	Neutral	+5.1%	Planned participation in two September 2025 healthcare and growth conferences.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news—including earnings, management changes, and conference/earnings-date notices—has generally seen the stock move in the same direction as the perceived tone of the announcements, with no clear pattern of divergence.

Recent Company History

Over the past six months, Pulmonx has reported Q3 2025 results with modest revenue growth but ongoing losses, announced leadership changes with updated executive compensation, and issued inducement equity grants tied to its 2025 Inducement Plan. It also communicated preliminary revenue and shifted earnings call timing, plus participated in investor conferences. This new notice of the Q4 and full-year 2025 earnings date continues the pattern of regular investor communications and scheduled updates following prior quarterly results and management transitions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Wednesday, March 4, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr^® Endobronchial Valve, Chartis^® Pulmonary Assessment System, LungTraX™ Platform, and StratX^® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.

Pulmonx^®, AeriSeal^®, Chartis^®, StratX^®, and Zephyr^® are registered trademarks and LungTraX™ is a trademark of Pulmonx Corporation.

Contact
Brian Johnston
Laine Morgan
Gilmartin Group
investors@pulmonx.com

FAQ

When will Pulmonx (LUNG) release Q4 and full year 2025 results?

Pulmonx will release fourth quarter and full year 2025 results after market close on March 4, 2026. According to the company, the release timing is scheduled for after the close of trading with a follow-up conference call the same day.

What time is the Pulmonx (LUNG) earnings conference call on March 4, 2026?

The Pulmonx conference call is scheduled to begin at 1:30 p.m. PT / 4:30 p.m. ET on March 4, 2026. According to the company, management will discuss the fourth quarter and full year 2025 financial results during the call.

How can investors access the Pulmonx (LUNG) webcast for the March 4, 2026 results?

Investors can access a live and archived webcast via the company's investor relations website at https://investors.pulmonx.com/. According to the company, the webcast will be available live and then archived for later replay on that page.

Will Pulmonx (LUNG) provide a replay of the March 4, 2026 earnings call?

Yes, a replay will be available as an archived webcast on the Pulmonx investor website after the live event. According to the company, the webcast will be posted on the investors page for subsequent on-demand access.

What topics will Pulmonx (LUNG) management discuss during the March 4, 2026 call?

Management will discuss the fourth quarter and full year 2025 financial results and related business developments. According to the company, the conference call is intended to review results and provide commentary to investors and analysts.